Twitch’s co-founder Kevin Lin recently raised $24 million for his blockchain game company, Metatheory. Notably, it is a16z that led the round with Pantera Capital and FTX Ventures as participating investors. According to Lin, the raised funds will help the company to work on its first Web3 game titled DuskBreakers.
Launched in August 2021, Kevin Lin’s Metatheory is focused on building Web3 games and franchises with strong IP. In addition, another two co-founders of the company are David Barthwell and JT Gleason.
“Dave and I started talking about the idea in early summer,” Lin told VentureBeat. “It was really the result of being in Taiwan and meeting a bunch of folks in crypto. We were exploring web 3 together and then decided to really take the plunge towards the end of summer.”
What is DuskBreakers?
As mentioned, DuskBreakers is the first sci-fi Web3 game that Metatheory is working on. The team launched the game in December last year and those who played the first mini-game got themselves a chance to mint a Genesis DuskBreakers NFT. The team later sold out all of its 10,000 Genesis DuskBreakers NFTs in 6 days.
As of writing, there’s no info on how P2E works in the game. But the idea is that players will get to join a squad of Breakers within the game, to explore a mysterious alien ship called Dusk. Thus, the name DuskBreakers.
According to Metatheory, the company will release the full play-and-earn game in Q4 this year. While waiting for the full launch, players can try out some free mini-games by downloading the game launcher. As of now, you do not need to hold any DuskBreaker NFT to play these games.
At last, if you want to know more about other sci-fi blockchain games like DuskBreakers, feel free to browse through our comprehensive guides in Mediaverse.
Subscribe to our hot social media and don’t miss anything else
All investment/financial opinions expressed by themediaverse.com are not recommendations.
This article is educational material.
As always, make your own research prior to making any kind of investment.